What Is Immunomedics stock
The Immunomedics stock blog features a wealth of information for investors and shareholders. The blog covers news, company updates, and new product launches.
Immunomedics has built up a reputation as a leading provider of humanized monoclonal antibodies used in the treatment of cancer. The company’s most notable products include IMA-637 and IMA-738, which are being used in clinical trials worldwide, along with IMA-131 and IMA-904, both of which are currently being
Visit the Immunomedics Blog to find information about news, product updates, industry trends and events, investor relations, and other company activities.
Blog about social media marketing:
Introduction:
Our Social Media Marketing blog offers tips, strategies and case studies on the most effective ways to market your business through social media.
Immunomedics Inc (IMMU)
The Immunomedics website is packed with helpful articles and information on the company and its products. We’ve got answers to questions like “how do I contact Immunomedics?” and “who are Immunomedics’ distributors?” Learn more about Immunomedics, their products, and their history.
Immunomedics is a biotechnology company focused on developing innovative therapeutic products that are based on the use of peptide vaccines. We believe that vaccination is the most effective and safest means to prevent and treat human diseases. IMMU was incorporated in 1994 as a public company with the objective of developing and commercializing vaccines that may be used to prevent or treat disease caused by a
Immunomedics, Inc. is dedicated to the discovery, development and commercialization of humanized monoclonal antibodies. We are focused on cancer and inflammation based indications, including autoimmune and inflammatory diseases, and cancer.
Gilead’s shares rise after $21 billion deal for Immunomedics
Shares of Gilead Sciences Inc. have climbed 5% in premarket trading on the heels of the company’s reported $21 billion acquisition of Immunomedics Inc.
Gilead has acquired Immunomedics for $11.50 a share or about $1.7 billion.
This comes just days after the biotech company announced that it was being sued
The world’s largest drug company by sales said Friday it was buying Immunomedics Inc., a company specializing in cancer treatments, for $21.3 billion. The deal would give Gilead Sciences Inc. new access to the lucrative market for immuno-oncology drugs — treatments that attack tumors by harnessing the immune system.
Gilead Sciences announced today that it has signed a definitive agreement to acquire Immunomedics Inc., a privately held biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer and inflammatory diseases.
Why Immunomedics Stock Is Screaming Higher Today
Why Immunomedics stock is screaming higher today? There are several reasons why this company could continue its upward momentum in 2017. First, the company is in the midst of rolling out a new product and a new commercial product to go along with it. Secondly, Immunomedics has a product pipeline that should be generating revenues and earnings for at least the next three years. Third
Immunomedics stock (IMMO) is up almost 30% today. We’ve seen it move higher since the $1.00 level after reporting better-than-expected earnings. The company just announced that they would begin a Phase 3 trial in the U.S., which could prove to be a game changer. If this drug gets approved, it could help
Today, immunomedics stock has moved higher by 6% in the past 24 hours. I expect this momentum to continue. This company is a global biopharmaceutical company focused on developing and commercializing novel, next-generation treatments to treat patients with serious diseases such as cancer, inflammation, and infectious disease.
Why Immunomedics Stock Is Screaming Higher Today
In today’s post, we look at the company’s strengths, what investors should know about the company, and why investors might want to consider buying shares in Immunomedics today.
On our popular stock blog, you can find articles on stocks in the biotech industry, plus posts on health care stocks, consumer products stocks, emerging markets, and more.
Saturday, September 28, 2009
If you have been searching for ways to optimize your site for search engines, then you are going to love this new website
As I write this blog post, I am holding Immunomedics (IMMU) in my portfolio. The company has been experiencing a significant increase in its stock price in the last two weeks. I’ve been tracking this stock for months now, but have never seen it move so high in such a short time span.
Today, the stock market is in a bullish mood after the recent sell-off. We have seen investors buying into some major stocks in hopes of a rebound. The overall market has moved higher in recent weeks and are seeing new highs on the daily charts.
Conclusion
Immunomedics stock Biologics (NASDAQ: IMMU) manufactures and markets biologic therapeutics that are used to treat autoimmune diseases in patients with inadequate response to standard treatment. Its product portfolio includes five commercialized products that treat inflammatory diseases or transplantation-related complications. The company has a growing pipeline of proprietary products targeting autoimmune diseases and conditions.
Immunomedics is one of the leading manufacturers of medical devices and solutions in the US, including sterile packaging, surgical kits and equipment, wound care products, and more.
